Cantor Fitzgerald Comments on PTC Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:PTCT)
PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) – Analysts at Cantor Fitzgerald dropped their FY2024 EPS estimates for PTC Therapeutics in a research report issued to clients and investors on Monday, July 1st. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($4.72) for the year, down […]
More Stories
Italy Arrests 9 for Allegedly Using Charities to Fund Hamas Terrorists
By Tom Ozimek Italian authorities have arrested nine people on suspicion of financing Hamas through a network of charities operating...
Winter Weather Cancels Over 1,000 Flights Across US
By Jacki Thrapp Travelers may need to pack their patience on Dec. 27 as winter weather in the Northeast prompted...
Trump Says 2026 Midterms Will Be Referendum on Prices, Economic Success
By Tom Ozimek President Donald Trump said he expects the 2026 midterm elections to hinge on prices and perceptions of...
Canada Offers Ukraine Additional $2.5 Billion in Aid
By Jacki Thrapp Canadian Prime Minister Mark Carney announced on Dec. 27 that Canada will provide an additional $2.5 billion...
Retail in 2025: A Roller Coaster Year—What’s Next in 2026
By Panos Mourdoukoutas The retail industry experienced significant volatility in 2025, as elevated inflation, a weakening labor market, rising household...
North Korean Media Says US-South Korea Submarine Deal Will Spark ‘Hot Arms Race’
By Guy Birchall North Korea’s state media said on Nov. 18 that South Korea’s U.S.-approved plan to build nuclear-powered submarines...